An IQVIA RWE Virtual Conference
Real World Evidence
Meet the Future with Confidence
Evidence generation and dissemination in a post-COVID world
COVID-19 is impacting all of us and challenging previous ways of working. This is a period of disruption.
However, we can embrace this new reality with confidence and adapt the way we work, the way we strategize, and the way we generate, use, and disseminate
real world evidence (RWE) to better inform decision making.
Stakeholders across the healthcare ecosystem (regulators, payers, providers, and patients) are adopting new solutions enabled by technology to navigate
this era of change.
In this new reality, RWE will take a more prominent role to improve patient outcomes, meet stakeholder needs, and answer business questions.
Join Pharmaceutical Executive®, IQVIA, and leading healthcare industry thought leaders to better understand the role and importance of RWE during and after COVID-19, what it means for your business today, and how you can plan for tomorrow with confidence.
Your computer
On-Demand
Free virtual event
Sessions and Panel Discussions
Hear from RWE speakers across the industry, learn about evidence generation and dissemination in our new reality, and discover how you can continue accelerating your business forward.
Keynote
Murray Aitken
Executive Director
IQVIA Institute of Human Data Science
Markus Gores, PhD
Vice President of Thought Leadership EMEA
IQVIA
Booth and Demos
Talk with us live via chat, ask questions, get answers, and experience live product demos.
Featured Speakers
Ian Bonzani
Senior Principal
Real World Networks Team
Healthcare Solutions
IQVIA
Mary New MBA, DPhil
Senior Principal
Patient Centered Endpoints
IQVIA
Anke van Engen
Senior Principal
Integrated Value Assessment
IQVIA
Nancy Dreyer, PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA
Lisa Taylor
Vice President
Head of Europe Consulting
EMEA Commercial and Consulting Services
IQVIA
Stella Karantzoulis, PhD
ABPP-CN
Senior Scientific Advisor
IQVIA
Andrea Spannheimer
Senior VP
Global Head of Real World Offerings
Innovations and Partnerships
IQVIA
Moke Sharma
Head of Development Operations & Quantitative Sciences
Alexion Pharmaceuticals
Konstantina Skaltsa, PhD
Associate Director Statistics
Patient Centered Endpoints
IQVIA
Markus Gores, PhD
Vice President
Thought Leadership EMEA
IQVIA
Murray Aitken
Executive Director
IQVIA Institute of
Human Data Science
Jean-François Bergmann, M.D
Professor of Internal Medicine
Pharmacology and Therapeutics
University of Paris
Christine Rutan, CPHQ
National Director
Real World Evidence and Health Information Technology
American Heart Association
Kathleen Gondek, PhD
Global Head of Evidence and Outcomes
Takeda
Mark McClellan, M.D., Ph.D
Director & Robert J. Margolis M.D. Professor of Business, Medicine and Policy
Margolis Center for Health Policy
Duke University
Ryan D. Kilpatrick, PhD
Head of Global Epidemiology
Pharmacovigilance & Patient Safety
AbbVie
Rhys Williams
Vice President
Global Health Economics and Outcomes Research (HEOR)
Sunovion
Rebecca Meisberger
Director
Real World Evidence
Global Patient Outcomes & Real World Evidence
Eli Lilly and Company
Future trends and
lasting impacts
What new approaches, technologies, and
behaviors are here to stay and what is their impact on the healthcare ecosystem?
For example, how will digital technologies like telehealth impact healthcare delivery?
How will the pressure on
site-based research and the need to reduce
study-induced burden on sites shift the balance between randomized clinical trials (RCTs) and RWE for regulatory submissions? How can RWD improve clinical trial efficiencies, fill evidence gaps, and accelerate approvals?
RWD and RCTs: Filling
evidence gaps
Accelerated RWE acceptance for decision making
Which current dynamics will further accelerate the
acceptance of RWE by
regulators and how will payers change their decision making criteria as they operate in a
more cost-constrained environment?
Featured Topics
Patient impacts and research participation
How are patients being affected by COVID-19, both in research and practice? What will be the
long-term impact on patients willingness to participate in research and share their health data?
Role of RWE across the product lifecycle
What will be the implications to pharma and the role of RWE across the product life cycle?
Will RWE generation and dissemination take a more prominent place in demonstrating value post-launch as part of commercialization efforts?
Your computer
Free virtual event
On-Demand
An IQVIA RWE Virtual Conference
COVID-19 is impacting all of us and challenging previous ways of working. This is a period of disruption.
However, we can embrace this new reality with confidence and adapt the way we work, the way we strategize, and the way we generate, use, and disseminate real world evidence (RWE) to better inform decision making.
Stakeholders across the healthcare ecosystem (regulators, payers, providers, and patients) are adopting new solutions enabled by technology to navigate this era of change.
In this new reality, RWE will take a more prominent role to improve patient outcomes, meet stakeholder needs, and answer business questions
Join Pharmaceutical Executive®, IQVIA, and leading healthcare industry thought-leaders to better understand the role and importance of RWE during and after COVID-19, what it means for your business today, and how you can plan for tomorrow with confidence.
Sessions and Panel Discussion
Hear from RWE speakers across the industry, learn about evidence generation and dissemination in our new reality, and discover how you can continue accelerating your business forward
Keynote
Murray Aitken
Executive Director
IQVIA Institute of Human Data Science
Markus Gores, PhD
Vice President of Thought Leadership EMEA
IQVIA
Booth and Demos
Talk with us live via online chat, ask questions, get answers, and experience live product demos
Featured Speakers
Lisa Taylor
Vice President
Head of Europe Consulting
EMEA Commercial and Consulting Services
IQVIA
Stella Karantzoulis, PhD
ABPP-CN
Senior Scientific Advisor
IQVIA
Anke van Engen
Senior Principal
Integrated Value Assessment
IQVIA
Mary New, MBA, DPhil
Senior Principal
Patient Centered Endpoints
IQVIA
Ian Bonzani
Senior Principal
Real World Networks Team
IQVIA
Nancy Dreyer, PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA
Featured Topics
Future trends and
lasting impacts
What new approaches, technologies, and
behaviors are here to stay and what is their impact on the healthcare ecosystem?
For example, how will digital technologies like telehealth impact healthcare delivery?
RWD and RCTs: Filling
evidence gaps
How will the pressure on
site-based research and the need to reduce study-induced burden on sites shift the balance between randomized clinical trials (RCTs) and RWE for regulatory submissions? How can RWD improve clinical trial efficiencies, fill evidence gaps, and accelerate approvals?
Accelerated RWE acceptance for decision making
Which current dynamics will further accelerate the
acceptance of RWE by
regulators and how will payers change their decision making criteria as they operate in a
more cost-constrained environment?
Patient impacts and research participation
How are patients being affected by COVID-19, both in research and practice? What will be the
long-term impact on patients willingness to participate in research and share their health data?
Role of RWE across the product lifecycle
What will be the implications to pharma and the role of RWE across the product life cycle?
Will RWE generation and dissemination take a more prominent place in demonstrating value post-launch as part of commercialization efforts?
Moke Sharma
Head of Development Operations & Quantitative Sciences
Alexion Pharmaceuticals
Konstantina Skaltsa, PhD
Associate Director Statistics
Patient Centered Endpoints
IQVIA
Markus Gores, PhD
Vice President
Thought Leadership EMEA
IQVIA
Murray Aitken
Executive Director
IQVIA Institute of Human Data Science
Andrea Spannheimer
Senior VP
Global Head of Real World Offerings
Innovations and Partnerships
IQVIA
Jean-François Bergmann, M.D
Professor of Internal Medicine
Pharmacology and Therapeutics
University of Paris
Christine Rutan, CPHQ
National Director
Real World Evidence and Health Information Technology
American Heart Association
Mark McClellan, M.D., Ph.D
Director & Robert J. Margolis M.D. Professor of Business, Medicine and Policy
Margolis Center for Health Policy
Duke University
Kathleen Gondek, PhD
Global Head of Evidence and Outcomes
Takeda
Ryan D. Kilpatrick, PhD
Head of Global Epidemiology
Pharmacovigilance & Patient Safety
AbbVie
Rhys Williams
Vice President
Global Health Economics and Outcomes Research (HEOR)
Sunovion
Rebecca Meisberger
Director
Real World Evidence
Global Patient Outcomes & Real World Evidence
Eli Lilly and Company